메뉴 건너뛰기




Volumn 18, Issue , 2015, Pages 263-267

Lipoprotein(a) - An independent causal risk factor for cardiovascular disease and current therapeutic options

Author keywords

Cardiovascular disease; Lipoprotein apheresis; Lipoprotein(a)

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN (A) ANTISENSE; ATORVASTATIN; EVOLOCUMAB; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; MIPOMERSEN; NICOTINIC ACID; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; BIOLOGICAL MARKER;

EID: 84928889604     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.039     Document Type: Article
Times cited : (49)

References (37)
  • 1
    • 0032542389 scopus 로고    scopus 로고
    • Lipoprotein(a) as a risk factor for coronary artery disease
    • discussion 86U
    • Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998, 82(12A):57U-66U. discussion 86U.
    • (1998) Am J Cardiol , vol.82 , Issue.12 A , pp. 57U-66U
    • Marcovina, S.M.1    Koschinsky, M.L.2
  • 2
    • 84896543027 scopus 로고    scopus 로고
    • Lipoprotein(a): the underestimated cardiovascular risk factor
    • Thompson G.R., Seed M. Lipoprotein(a): the underestimated cardiovascular risk factor. Heart 2014, 100(7):534-535.
    • (2014) Heart , vol.100 , Issue.7 , pp. 534-535
    • Thompson, G.R.1    Seed, M.2
  • 3
    • 47649091099 scopus 로고
    • A new serum type system in man-the Lp system
    • Berg K. A new serum type system in man-the Lp system. Acta Pathol Microbiol Scand 1963, 59:369-382.
    • (1963) Acta Pathol Microbiol Scand , vol.59 , pp. 369-382
    • Berg, K.1
  • 5
    • 67651210632 scopus 로고    scopus 로고
    • Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality
    • Emerging Risk Factors Collaboration
    • Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., White I.R., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302(4):412-423. Emerging Risk Factors Collaboration.
    • (2009) JAMA , vol.302 , Issue.4 , pp. 412-423
    • Erqou, S.1    Kaptoge, S.2    Perry, P.L.3    Di Angelantonio, E.4    Thompson, A.5    White, I.R.6
  • 6
    • 1842829035 scopus 로고    scopus 로고
    • Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models
    • Boffa M.B., Marcovina S.M., Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004, 37(5):333-343.
    • (2004) Clin Biochem , vol.37 , Issue.5 , pp. 333-343
    • Boffa, M.B.1    Marcovina, S.M.2    Koschinsky, M.L.3
  • 7
    • 84871674237 scopus 로고    scopus 로고
    • Lipoprotein(a): resurrected by genetics
    • Kronenberg F., Utermann G. Lipoprotein(a): resurrected by genetics. J Intern Med 2013, 273(1):6-30.
    • (2013) J Intern Med , vol.273 , Issue.1 , pp. 6-30
    • Kronenberg, F.1    Utermann, G.2
  • 8
    • 0025311925 scopus 로고
    • Lipoprotein (a). Heterogeneity and biological relevance
    • Scanu A.M., Fless G.M. Lipoprotein (a). Heterogeneity and biological relevance. J Clin Invest 1990, 85(6):1709-1715.
    • (1990) J Clin Invest , vol.85 , Issue.6 , pp. 1709-1715
    • Scanu, A.M.1    Fless, G.M.2
  • 9
    • 84898025084 scopus 로고    scopus 로고
    • Lipoprotein(a) in various conditions: to keep a sense of proportions
    • Kronenberg F. Lipoprotein(a) in various conditions: to keep a sense of proportions. Atherosclerosis 2014, 234(1):249-251.
    • (2014) Atherosclerosis , vol.234 , Issue.1 , pp. 249-251
    • Kronenberg, F.1
  • 10
    • 0023393811 scopus 로고
    • Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma
    • Utermann G., Menzel H.J., Kraft H.G., Duba H.C., Kemmler H.G., Seitz C. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987, 80(2):458-465.
    • (1987) J Clin Invest , vol.80 , Issue.2 , pp. 458-465
    • Utermann, G.1    Menzel, H.J.2    Kraft, H.G.3    Duba, H.C.4    Kemmler, H.G.5    Seitz, C.6
  • 11
    • 77951637599 scopus 로고    scopus 로고
    • Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants
    • Erqou S., Thompson A., Di Angelantonio E., Saleheen D., Kaptoge S., Marcovina S., et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010, 55(19):2160-2167.
    • (2010) J Am Coll Cardiol , vol.55 , Issue.19 , pp. 2160-2167
    • Erqou, S.1    Thompson, A.2    Di Angelantonio, E.3    Saleheen, D.4    Kaptoge, S.5    Marcovina, S.6
  • 12
    • 84893853699 scopus 로고    scopus 로고
    • Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)
    • Khera A.V., Everett B.M., Caulfield M.P., Hantash F.M., Wohlgemuth J., Ridker P.M., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Circulation 2014, 129(6):635-642.
    • (2014) Circulation , vol.129 , Issue.6 , pp. 635-642
    • Khera, A.V.1    Everett, B.M.2    Caulfield, M.P.3    Hantash, F.M.4    Wohlgemuth, J.5    Ridker, P.M.6
  • 13
    • 84885954764 scopus 로고    scopus 로고
    • Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study
    • Kamstrup P.R., Nordestgaard B.G. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol 2013, 1(3):220-227.
    • (2013) Lancet Diabetes Endocrinol , vol.1 , Issue.3 , pp. 220-227
    • Kamstrup, P.R.1    Nordestgaard, B.G.2
  • 14
    • 84872876060 scopus 로고    scopus 로고
    • Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography
    • Safarova M.S., Ezhov M.V., Afanasieva O.I., Matchin Y.G., Atanesyan R.V., Adamova I.Y., et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler Suppl 2013, 14(1):93-99.
    • (2013) Atheroscler Suppl , vol.14 , Issue.1 , pp. 93-99
    • Safarova, M.S.1    Ezhov, M.V.2    Afanasieva, O.I.3    Matchin, Y.G.4    Atanesyan, R.V.5    Adamova, I.Y.6
  • 15
    • 67049167090 scopus 로고    scopus 로고
    • Genetically elevated lipoprotein(a) and increased risk of myocardial infarction
    • Kamstrup P.R., Tybjaerg-Hansen A., Steffensen R., Nordestgaard B.G. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009, 301(22):2331-2339.
    • (2009) JAMA , vol.301 , Issue.22 , pp. 2331-2339
    • Kamstrup, P.R.1    Tybjaerg-Hansen, A.2    Steffensen, R.3    Nordestgaard, B.G.4
  • 16
    • 84893333521 scopus 로고    scopus 로고
    • Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population
    • Kamstrup P.R., Tybjaerg-Hansen A., Nordestgaard B.G. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014, 63(5):470-477.
    • (2014) J Am Coll Cardiol , vol.63 , Issue.5 , pp. 470-477
    • Kamstrup, P.R.1    Tybjaerg-Hansen, A.2    Nordestgaard, B.G.3
  • 17
    • 35148892823 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
    • Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007, 28(19):2375-2414.
    • (2007) Eur Heart J , vol.28 , Issue.19 , pp. 2375-2414
    • Graham, I.1    Atar, D.2    Borch-Johnsen, K.3    Boysen, G.4    Burell, G.5    Cifkova, R.6
  • 18
    • 8844246477 scopus 로고    scopus 로고
    • Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
    • Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Arterioscler Thromb Vasc Biol 2004, 24(8):e149-e161.
    • (2004) Arterioscler Thromb Vasc Biol , vol.24 , Issue.8 , pp. e149-e161
    • Grundy, S.M.1    Cleeman, J.I.2    Merz, C.N.3    Brewer, H.B.4    Clark, L.T.5    Hunninghake, D.B.6
  • 20
    • 2442520797 scopus 로고    scopus 로고
    • Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis
    • Insull W., McGovern M.E., Schrott H., Thompson P., Crouse J.R., Zieve F., et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004, 164(10):1121-1127.
    • (2004) Arch Intern Med , vol.164 , Issue.10 , pp. 1121-1127
    • Insull, W.1    McGovern, M.E.2    Schrott, H.3    Thompson, P.4    Crouse, J.R.5    Zieve, F.6
  • 21
    • 84877299845 scopus 로고    scopus 로고
    • HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment
    • Hps Thrive Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013, 34(17):1279-1291.
    • (2013) Eur Heart J , vol.34 , Issue.17 , pp. 1279-1291
  • 22
    • 84904252744 scopus 로고    scopus 로고
    • Effects of extended-release niacin with laropiprant in high-risk patients
    • Hps Thrive Collaborative Group. Landray M.J., Haynes R., Hopewell J.C., Parish S., Aung T., Tomson J., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014, 371(3):203-212.
    • (2014) N Engl J Med , vol.371 , Issue.3 , pp. 203-212
    • Landray, M.J.1    Haynes, R.2    Hopewell, J.C.3    Parish, S.4    Aung, T.5    Tomson, J.6
  • 24
    • 84864239186 scopus 로고    scopus 로고
    • Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia
    • Gelsinger C., Steinhagen-Thiessen E., Kassner U. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia. Drugs 2012, 72(11):1445-1455.
    • (2012) Drugs , vol.72 , Issue.11 , pp. 1445-1455
    • Gelsinger, C.1    Steinhagen-Thiessen, E.2    Kassner, U.3
  • 25
    • 84870065743 scopus 로고    scopus 로고
    • Emerging therapeutic agents to lower lipoprotein(a) levels
    • Kolski B., Tsimikas S. Emerging therapeutic agents to lower lipoprotein(a) levels. Curr Opin Lipidol 2012, 23(6):560-568.
    • (2012) Curr Opin Lipidol , vol.23 , Issue.6 , pp. 560-568
    • Kolski, B.1    Tsimikas, S.2
  • 26
    • 84892679366 scopus 로고    scopus 로고
    • Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) randomized trial
    • Koren M.J., Giugliano R.P., Raal F.J., Sullivan D., Bolognese M., Langslet G., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129(2):234-243.
    • (2014) Circulation , vol.129 , Issue.2 , pp. 234-243
    • Koren, M.J.1    Giugliano, R.P.2    Raal, F.J.3    Sullivan, D.4    Bolognese, M.5    Langslet, G.6
  • 27
    • 0036959309 scopus 로고    scopus 로고
    • Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP
    • Julius U., Metzler W., Pietzsch J., Fassbender T., Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: lipidfiltration and HELP. Int J Artif Organs 2002, 25(12):1180-1188.
    • (2002) Int J Artif Organs , vol.25 , Issue.12 , pp. 1180-1188
    • Julius, U.1    Metzler, W.2    Pietzsch, J.3    Fassbender, T.4    Klingel, R.5
  • 28
    • 0032790486 scopus 로고    scopus 로고
    • Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation
    • Richter W.O., Donner M.G., Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999, 3(3):203-208.
    • (1999) Ther Apher , vol.3 , Issue.3 , pp. 203-208
    • Richter, W.O.1    Donner, M.G.2    Schwandt, P.3
  • 29
    • 84894257728 scopus 로고    scopus 로고
    • Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?
    • Rosada A., Kassner U., Vogt A., Willhauck M., Parhofer K., Steinhagen-Thiessen E. Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?. Artif Organs 2014, 38(2):135-141.
    • (2014) Artif Organs , vol.38 , Issue.2 , pp. 135-141
    • Rosada, A.1    Kassner, U.2    Vogt, A.3    Willhauck, M.4    Parhofer, K.5    Steinhagen-Thiessen, E.6
  • 31
    • 72649086379 scopus 로고    scopus 로고
    • Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)
    • Kassner U., Vogt A., Rosada A., Barz F., Giannakidou-Jordan E., Berthold H.K., et al. Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a). Atheroscler Suppl 2009, 10(5):85-88.
    • (2009) Atheroscler Suppl , vol.10 , Issue.5 , pp. 85-88
    • Kassner, U.1    Vogt, A.2    Rosada, A.3    Barz, F.4    Giannakidou-Jordan, E.5    Berthold, H.K.6
  • 33
    • 84872848174 scopus 로고    scopus 로고
    • Lipoprotein apheresis: state of the art and novelties
    • Stefanutti C., Julius U. Lipoprotein apheresis: state of the art and novelties. Atheroscler Suppl 2013, 14(1):19-27.
    • (2013) Atheroscler Suppl , vol.14 , Issue.1 , pp. 19-27
    • Stefanutti, C.1    Julius, U.2
  • 34
    • 61549101898 scopus 로고    scopus 로고
    • Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events
    • Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009, 6(3):229-239.
    • (2009) Nat Clin Pract Cardiovasc Med , vol.6 , Issue.3 , pp. 229-239
    • Jaeger, B.R.1    Richter, Y.2    Nagel, D.3    Heigl, F.4    Vogt, A.5    Roeseler, E.6
  • 35
    • 84890904215 scopus 로고    scopus 로고
    • Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study
    • Leebmann J., Roeseler E., Julius U., Heigl F., Spitthoever R., Heutling D., et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study. Circulation 2013, 128(24):2567-2576.
    • (2013) Circulation , vol.128 , Issue.24 , pp. 2567-2576
    • Leebmann, J.1    Roeseler, E.2    Julius, U.3    Heigl, F.4    Spitthoever, R.5    Heutling, D.6
  • 36
    • 84872841551 scopus 로고    scopus 로고
    • Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern
    • von Dryander M., Fischer S., Passauer J., Muller G., Bornstein S.R., Julius U. Differences in the atherogenic risk of patients treated by lipoprotein apheresis according to their lipid pattern. Atheroscler Suppl 2013, 14(1):39-44.
    • (2013) Atheroscler Suppl , vol.14 , Issue.1 , pp. 39-44
    • von Dryander, M.1    Fischer, S.2    Passauer, J.3    Muller, G.4    Bornstein, S.R.5    Julius, U.6
  • 37
    • 63349111341 scopus 로고    scopus 로고
    • Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging
    • Bohl S., Kassner U., Eckardt R., Utz W., Mueller-Nordhorn J., Busjahn A., et al. Single lipoprotein apheresis session improves cardiac microvascular function in patients with elevated lipoprotein(a): detection by stress/rest perfusion magnetic resonance imaging. Ther Apher Dial 2009, 13(2):129-137.
    • (2009) Ther Apher Dial , vol.13 , Issue.2 , pp. 129-137
    • Bohl, S.1    Kassner, U.2    Eckardt, R.3    Utz, W.4    Mueller-Nordhorn, J.5    Busjahn, A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.